Tomas Jelinek (@tomasjelinekmd) 's Twitter Profile
Tomas Jelinek

@tomasjelinekmd

Associate Professor, Dept. of Hematooncology, University Hospital Ostrava; Head of flow cytometry core, Blood Cancer Research Group, University of Ostrava

ID: 1431986544009793541

calendar_today29-08-2021 18:34:03

248 Tweet

183 Followers

207 Following

Ben Derman (@bdermanmd) 's Twitter Profile Photo

🚨Out now in Blood Journal led by Tadeusz Kubicki We studied blood mass spec (EXENT) as an MRD tool post-transplant in myeloma. What made this analysis unique is that IgG M-proteins persist after destruction of the culprit cells due to recycling /1 #mmMRD doi.org/10.1182/blood.…

🚨Out now in <a href="/BloodJournal/">Blood Journal</a> led by <a href="/t_kubicki/">Tadeusz Kubicki</a> 
We studied blood mass spec (EXENT) as an MRD tool post-transplant in myeloma. What made this analysis unique is that IgG M-proteins persist after destruction of the culprit cells due to recycling /1 #mmMRD doi.org/10.1182/blood.…
Francesco Maura (@francescomaura4) 's Twitter Profile Photo

New paper out today in Blood Journal from the fantastic collaboration between Heidelberg University Heidelberg Myeloma University of Miami Memorial Sloan Kettering Cancer Center 🎉. Paper title: "The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma" #msmm (1/x)

New paper out today in <a href="/BloodJournal/">Blood Journal</a> from the fantastic collaboration between <a href="/HeidelbergU/">Heidelberg University</a> <a href="/HDMyeloma/">Heidelberg Myeloma</a> <a href="/univmiami/">University of Miami</a> <a href="/MSKCancerCenter/">Memorial Sloan Kettering Cancer Center</a> 🎉. Paper title: "The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma" #msmm (1/x)
Rahul Banerjee, MD, FACP (@rahulbanerjeemd) 's Twitter Profile Photo

1/ IFM 2018-04 in Blood Journal! Ph2 🇫🇷 trial of "double" ASCT in high-risk #MMsm, not tandem per se. n=50, 60% UHR. 80% PFS at 2.5 yrs for HRMM! Similar to MUKnine. Much less dropout than BMT-CTN 0702... double > tandem for pt tolerability (if done)? ashpublications.org/blood/article/…

1/ IFM 2018-04 in <a href="/BloodJournal/">Blood Journal</a>!

Ph2 🇫🇷 trial of "double" ASCT in high-risk #MMsm, not tandem per se. n=50, 60% UHR.

80% PFS at 2.5 yrs for HRMM! Similar to MUKnine.

Much less dropout than BMT-CTN 0702... double &gt; tandem for pt tolerability (if done)?

ashpublications.org/blood/article/…
Samer Al Hadidi, MD,MS,FACP (@hadidisamer) 's Twitter Profile Photo

Myeloma is a curable malignancy #mmsm Yes it is curable The cure rate is not ideal (not all/most patients are cured)- there is still work to be done to improve We estimate that one out of three patients with standard risk myeloma (vast majority of cases) are cured 🧵

Myeloma is a curable malignancy #mmsm 

Yes it is curable

The cure rate is not ideal (not all/most patients are cured)- there is still work to be done to improve

We estimate that one out of three patients with standard risk myeloma (vast majority of cases) are cured 

🧵
Meral Beksac (@mbeksac56) 's Twitter Profile Photo

COMy RWE from France confirms extramedullary disease still an unmet need despite CART as reported from RCT data by Nico Gagelmann Mohamad Mohty EMN we need specific trials for this subgroup Tomas Jelinek

<a href="/COMyCongress/">COMy</a>  RWE from France confirms extramedullary disease  still an unmet need despite CART as reported from RCT data by <a href="/NicoGagelmann/">Nico Gagelmann</a> <a href="/Mohty_EBMT/">Mohamad Mohty</a> <a href="/EMN_EuMMnet/">EMN</a> we need specific trials for this subgroup <a href="/TomasJelinekMD/">Tomas Jelinek</a>
Saurabh Zanwar (@zanwarsaurabh) 's Twitter Profile Photo

Out now in Journal of Clinical Oncology! Our collaborative work: 𝐌𝐨𝐝𝐢𝐟𝐢𝐞𝐝 𝐒𝐭𝐚𝐠𝐢𝐧𝐠 𝐒𝐲𝐬𝐭𝐞𝐦 𝐟𝐨𝐫 𝐖𝐚𝐥𝐝𝐞𝐧𝐬𝐭𝐫ö𝐦 𝐦𝐚𝐜𝐫𝐨𝐠𝐥𝐨𝐛𝐮𝐥𝐢𝐧𝐞𝐦𝐢𝐚 (𝐌𝐒𝐒-𝐖𝐌) ascopubs.org/doi/10.1200/JC… Prashant Kapoor Shaji Kumar Vincent Rajkumar Jithma Abeykoon, M.D. Jonas Paludo A brief 🧵 1/

Czech Society for Analytical Cytometry (@csac_cz) 's Twitter Profile Photo

Join our summer school, 8-11th July in Brno! 4days full of #flow #cytometry and hands-on workshop. Detailed info & registration 👇👇👇 csac.cz/cs/kalendar-ak…

Join our summer school, 8-11th July in Brno! 4days full of #flow #cytometry and hands-on workshop. Detailed info &amp; registration 👇👇👇
csac.cz/cs/kalendar-ak…
Tomas Jelinek (@tomasjelinekmd) 's Twitter Profile Photo

I always defended this agent as we observed very deep and durable responses in some of our patients. It is good to have this drug available, especially if the dosing might be once every two months in the future. Congratulations to the authors! nej.md/3wTS3pA

Vincent Rajkumar (@vincentrk) 's Twitter Profile Photo

Here is a bit of history. Here is the original myeloma review that taught us the disease — prior to all the new drugs. From 1994. By Ray Alexanian & Thanos Dimopoulos nejm.org/doi/pdf/10.105…

Here is a bit of history. Here is the original myeloma review that taught us the disease — prior to all the new drugs. From 1994. By Ray Alexanian &amp; <a href="/thanosdimop/">Thanos Dimopoulos</a> nejm.org/doi/pdf/10.105…
Saurabh Zanwar (@zanwarsaurabh) 's Twitter Profile Photo

Out now in Journal of Hematology and Oncology: Impact of Extramedullary Multiple Myeloma on Outcomes with Ide-cel: jhoonline.biomedcentral.com/articles/10.11… Shaji Kumar Yi Lin Krina Patel Surbhi Sidana, MD #dorishansen Moffitt Cancer Center BMC Top line results and a brief 🧵 1/

Out now in Journal of Hematology and Oncology:

Impact of Extramedullary Multiple Myeloma on Outcomes with Ide-cel:

jhoonline.biomedcentral.com/articles/10.11…

<a href="/myelomaMD/">Shaji Kumar</a> <a href="/YiLinMDPhD/">Yi Lin</a> <a href="/DrKrinaPatel/">Krina Patel</a> 
<a href="/SurbhiSidanaMD/">Surbhi Sidana, MD</a> #dorishansen <a href="/MoffittNews/">Moffitt Cancer Center</a> <a href="/BioMedCentral/">BMC</a> 

Top line results and a brief 🧵 1/
Mattia D’Agostino (@dagostino_md) 's Twitter Profile Photo

Finally out in Blood Cancer Journal! Amp1q worse than Gain1q. Gain1q may benefit from KRd+transplant. Additional copies of 1q induced transcriptomic changes. Isolated Amp1q is already bad but when other high risk features are present PFS<12 months! #mmsm nature.com/articles/s4140…

Mraz Lab (@mrazlab) 's Twitter Profile Photo

Delighted to share our latest publication (Hoferkova et al., Leukemia):novel co-culture model inducing ~50% proliferation of primary CLL cells.The co-cultures mimic the gene expression of lymph node CLL cells + Pan-RAF inhibitors block CLL proliferation. rdcu.be/dKO3a

Delighted to share our latest publication (Hoferkova et al., Leukemia):novel co-culture model inducing ~50% proliferation of primary CLL cells.The co-cultures mimic the gene expression of lymph node CLL cells + Pan-RAF inhibitors block CLL proliferation. rdcu.be/dKO3a
Bruno Paiva (@brunopaiva_unav) 's Twitter Profile Photo

One of the best things about our work is the people you get to know and learn from! Catarina Maia Juanjo Garcés Tomas Jelinek David Žihala were in our laboratory, gave their very best, and now are flying high in their work places. Friendship photographed in the last #ASH24 dinner

One of the best things about our work is the people you get to know and learn from!

<a href="/Catarina_asMaia/">Catarina Maia</a> <a href="/juanjogrcs/">Juanjo Garcés</a> <a href="/TomasJelinekMD/">Tomas Jelinek</a> <a href="/DZihala/">David Žihala</a> were in our laboratory, gave their very best, and now are flying high in their work places. Friendship photographed in the last #ASH24 dinner
Elias K. Mai MD (@eliaskarlmai) 's Twitter Profile Photo

For those who want to carefully read and examine our GMMG-HD7 results from #ASH24 #mmsm Check out: ascopubs.org/doi/10.1200/JC… Big thanks to our patients and all collaborators! Heidelberg Myeloma Dept. of Hematology, Oncology, Rheumatology UK-HD